The board of directors (the ?Board?) of SciClone Pharmaceuticals (Holdings) Limited (the ?Company?) announced that with effect from May 16, 2024, the address of the principal place of business in Hong Kong of the Company has changed from 3401A, Windsor House, 311 Gloucester Road, Causeway Bay, Hong Kong to 5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
18.72 HKD | +0.86% |
|
+0.86% | +34.48% |
26/06 | SciClone Pharmaceuticals Limited Announces Retirement of Wang Haixia as Non-Executive Director | CI |
21/06 | SciClone Pharmaceuticals Limited(SEHK:6600) dropped from S&P Global BMI Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+34.48% | 145.55Cr | |
+1.87% | 9.42TCr | |
-4.08% | 3.78TCr | |
-13.26% | 3.25TCr | |
+73.38% | 2.78TCr | |
-11.58% | 1.61TCr | |
-1.66% | 1.42TCr | |
-11.67% | 1.14TCr | |
+190.36% | 1.11TCr | |
-52.61% | 908.81Cr |
- Stock Market
- Equities
- 6600 Stock
- News SciClone Pharmaceuticals (Holdings) Limited
- Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong